Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 620 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine Clear all
Not listed Phase 2 Interventional

Science-Based Treatment for Opioid-Dependent Adolescents

NCT00182572
View directory record Official record
Conditions
Opioid-Dependence Among Adolescents
Interventions
buprenorphine, naltrexone, behavior therapy, voucher-based contingency management
Drug · Procedure
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
13 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2008 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 19, 2026, 1:16 AM EDT
Withdrawn Phase 4 Interventional

Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women

NCT04212065
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 41 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Buprenorphine Dosing Interval - 5

NCT00000209
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Clinical Rescue Protocol - 2

NCT00000206
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Early Phase 1 Interventional Results available

Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine

NCT05076370
View directory record Official record
Conditions
Addiction
Interventions
CBD Day 1, CBD Day 2, CBD Day 3
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry

NCT01999946
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Extended-Release Naltrexone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 19, 2026, 1:16 AM EDT
Recruiting Phase 1 Interventional

Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

NCT04161066
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin with facilitated counseling
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 1:16 AM EDT
Completed No phase listed Observational

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

NCT03718104
View directory record Official record
Conditions
Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
Interventions
Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, Breast milk analysis
Other · Genetic
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 19, 2026, 1:16 AM EDT
Not listed No phase listed Observational

Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing

NCT05307458
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
United Health Services Hospitals, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 19, 2026, 1:16 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1

NCT00000326
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Heroin Dependence
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 3 Interventional

Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 4 Interventional Results available

Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion

NCT04254081
View directory record Official record
Conditions
Procedural Pain, Buprenorphine, Adjuvants, Anesthesia, Dilation and Evacuation, Analgesics
Interventions
Buprenorphine 0.15 MG, Lidocaine 1% Injectable Solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 19, 2026, 1:16 AM EDT
Recruiting Not applicable Interventional

Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment

NCT07024498
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
care coordination implementation strategies
Other
Lead sponsor
University of California, Davis
Other
Eligibility
14 Years and older
Enrollment
3,492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
El Centro, California • Irvine, California • Placerville, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder

NCT04240093
View directory record Official record
Conditions
Opioid-use Disorder, Medication Adherence, Health Care Utilization
Interventions
Behavioral Activation (BA) Therapy, Substance Abuse and Health Navigation Counseling, Medications for Opioid Use Disorder
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 19, 2026, 1:16 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Better Options for Chronic Cancer Pain

NCT06574009
View directory record Official record
Conditions
Chronic Pain, Cancer Survivor, Opioid Dependence
Interventions
Multimodal pain care, Medication optimization, Buprenorphine rotation, Opioid tapering
Behavioral · Drug · Device + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 19, 2026, 1:16 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

NCT06854029
View directory record Official record
Conditions
HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

RCT Comparing Methadone and Buprenorphine in Pregnant Women

NCT00271219
View directory record Official record
Conditions
Opioid Related Disorders, Pregnancy, Opioid Dependence
Interventions
Methadone, Buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
6
States / cities
Baltimore, Maryland • Detroit, Michigan • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)

NCT01708707
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Interventions
Buprenorphine, Morphine Sulfate
Drug
Lead sponsor
Pediatrix
Other
Eligibility
Up to 1 Year
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 19, 2026, 1:16 AM EDT
Not yet recruiting Phase 4 Interventional

Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation

NCT07469501
View directory record Official record
Conditions
Opioid Use Disorder, Fentanyl
Interventions
Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 1Phase 2 Interventional

Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1

NCT00000320
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine formulation: liquid vs. tablet
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Not applicable Interventional Results available

Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD

NCT03658642
View directory record Official record
Conditions
Clinical Decision Support, Buprenorphine, Opioid-use Disorder
Interventions
Clinical Decision Support (CDS)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
5,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Gardendale, Alabama • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 19, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Buprenorphine and Naloxone Combination Study - 10

NCT00015288
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 1:16 AM EDT